Pancreatic Cancer Research

ResearcherUniversity of Wisconsin–MadisonActive in the last 2 years

Weibo Cai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4641-0833; OpenAlex author ID A5085412582. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
19
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 3 papers · 2017: 2 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 12

  1. Cerenkov radiation modulates the extracellular matrix for improved pancreatic cancer chemotherapy. Co-author DOI 10.1016/j.celbio.2025.100221↗
  2. Noninvasive Evaluation of Trop2 Expression Using 64Cu-NOTA-Trodelvy-F(ab')2 in Gastric and Pancreatic Cancer. Last author DOI 10.1021/acs.molpharmaceut.5c01223↗
  3. Optical image-guided therapy of pancreatic cancer with an ultra-small bispecific protein. Last author DOI 10.1007/s00259-023-06186-4↗
  4. ImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer. Last author DOI 10.1007/s00259-021-05563-1↗
  5. ImmunoPET/NIRF/Cerenkov multimodality imaging of ICAM-1 in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00259-021-05216-3↗
  6. 86/90Y-Labeled Monoclonal Antibody Targeting Tissue Factor for Pancreatic Cancer Theranostics. Last author DOI 10.1021/acs.molpharmaceut.0c00127↗
  7. ImmunoPET imaging of tissue factor expression in pancreatic cancer with 89Zr-Df-ALT-836. Last author DOI 10.1016/j.jconrel.2017.08.029↗
  8. ImmunoPET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer with a Dual-Labeled Bispecific Antibody Fragment. Last author DOI 10.1021/acs.molpharmaceut.6b01123↗
  9. Molecular Imaging of Pancreatic Cancer with Antibodies. Last author DOI 10.1021/acs.molpharmaceut.5b00626↗
  10. ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer. Last author DOI 10.1021/acs.molpharmaceut.6b00132↗
  11. Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-15-2054↗
  12. Immuno-PET of tissue factor in pancreatic cancer. Last author DOI 10.2967/jnumed.112.105460↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dalong Ni · 2 shared papers, 2020–2026 · strength 0.40
  2. Dawei Jiang · 3 shared papers, 2020–2022 · strength 0.39
  3. Christopher G. England · 5 shared papers, 2016–2017 · strength 0.34
  4. Tao Wang · 1 shared paper, 2026 · strength 0.29
  5. Changjing Zuo · 1 shared paper, 2026 · strength 0.29
  6. Weiwei Su · 1 shared paper, 2026 · strength 0.29
  7. Miao Li · 2 shared papers, 2021–2022 · strength 0.28
  8. Weiyu Chen · 2 shared papers, 2021–2022 · strength 0.28
  9. Reinier T. Hernandez · 4 shared papers, 2016–2017 · strength 0.27
  10. Wenyu Song · 1 shared paper, 2023 · strength 0.26
  11. Xiaoli Lan · 1 shared paper, 2023 · strength 0.26
  12. Wenpeng Huang · 1 shared paper, 2025 · strength 0.25
  13. Lei Kang · 1 shared paper, 2025 · strength 0.25
  14. Min Zhou · 1 shared paper, 2022 · strength 0.15
  15. Haiming Luo · 2 shared papers, 2016–2017 · strength 0.12
  16. Carolina A. Ferreira · 1 shared paper, 2020 · strength 0.11
  17. Hyung‐Jun Im · 1 shared paper, 2016 · strength 0.05
  18. Dong Soo Lee · 1 shared paper, 2016 · strength 0.05
  19. Hao Hong · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.